United States
Print page content Print
Increase text size Decrease text size
Text Size
CYTOPOINT is now approved for the treatment of allergic dermatitis! Learn more
Cytopoint logo

This site is intended for U.S.
animal healthcare professionals

The first monoclonal antibody (mAB) therapy for chronic canine allergic and atopic dermatitis1

The first monoclonal (mAB) antibody therapy for chronic canine atopic dermatitis1

CYTOPOINT® mimics the dog’s natural immune function; it targets IL-31, which is involved in the cycle of itch and inflammation2

A closer look at the MOA of CYTOPOINT

A closer look at the MOA of CYTOPOINT

How CYTOPOINT works

  • CYTOPOINT is a monoclonal antibody (mAb)* treatment for dogs that specifically targets and neutralizes canine IL-31, an important cytokine involved in sending the itch signal to the brain in chronic atopic dermatitis2
  • Because it is highly targeted to a specific cytokine involved in canine atopic dermatitis, CYTOPOINT has minimal impact on normal immune functions3
  • CYTOPOINT is eliminated via normal protein degradation pathways in the same way as naturally occurring antibodies§; metabolism does not involve the liver or kidneys
  • Monoclonal antibody (mAb): a single, homogenous antibody preparation derived from a single lineage of B cells. Monoclonal antibody therapy is designed to mimic a normal immune function by recognizing and binding to one single segment, or epitope, on a particular target antigen.4,5
  • Interleukin 31 (IL-31): a cytokine that triggers the process of sending itch signals to the brain.2
  • Cytokine: a protein that signals other cells by binding to receptors on those cells.6
  • mAbs are catabolized within cells into amino acids and peptides. They are not metabolized in the liver or kidneys, converted into reactive or toxic metabolites, or excreted in urine. Thus, they are highly unlikely to induce liver or kidney toxicity.

Indications: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.